Resources

In-the-Know With Verastem Oncology

Access the latest posters, presentations and publications from Verastem Oncology below:

Feature resources

Animation Video Demonstrating How Avutometinib and Novel Combinations Better Control RAS Pathway and Parallel Pathway Signaling

Jonathan Pachter, PhD, Chief Scientific Officer

Verastem Oncology 2021

Jonathan Pachter, Chief Scientific Officer, Discusses the Unique Properties of RAF/MEK Clamp Avutometinib

Jonathan Pachter, PhD, Chief Scientific Officer

Verastem Oncology 2022

Avutometinib

A Phase 3, Randomized Trial Evaluating Avutometinib Plus Defactinib Compared With Investigator’s Choice of Therapy (ICT) in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC): GOG-3097/ENGOT-ov81/NCRI/RAMP 301

Rachel N. Grisham, Bradley J. Monk, Els Van Nieuwenhuysen, Kathleen N. Moore, Michel Fabbro, David M. O’Malley, Ana Oaknin, Premal H. Thaker, Amit M. Oza, Nicoletta Colombo, Stephanie Lustgarten, Hagop Youssoufian, Susana N. Banerjee

SGO Annual Meeting on Women’s Cancer March 16-18, 2024, San Diego, CA.

Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC): A Subgroup Analysis of ENGOT-ov60/GOG3052/RAMP 201 Part A

Susana N. Banerjee, Els Van Nieuwenhuysen, Alessandro D. Santin, Kari L. Ring, Nicoletta Colombo, Premal H. Thaker, Emily N. Prendergast, Andrew R. Clamp, Isabelle Ray-Coquard, Hye Sook Chon, Kathleen N. Moore, Erin A. Salinas, Peter G. Rose, David M. O’Malley, Ana Oaknin, Bradley J. Monk, Robert W. Holloway, Gregg Newman, John W. Moroney, Toon Van Gorp, Elsa Kalbacher, Christine Gennigens, Nicholas E. Wojtynek, Stephanie Lustgarten, Rachel N. Grisham

SGO Annual Meeting on Women’s Cancer March 16-18, 2024, San Diego, CA

Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer

Blair McNamara, Michelle Greenman, Cem Demirkiran, Tobias Max Phillip Hartwich, Stefania Bellone, Diego Manavella, Levent Mutlu, Margherita Zipponi, Yang Yang-Hartwich, Kevin Yang, Elena Ratner, Peter E. Schwartz, Silvia Coma, Jonathan Pachter, Alessandro D. Santin

SGO Annual Meeting on Women’s Cancer March 16-18, 2024, San Diego, CA

Efficacy and Safety of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer Following Prior Systemic Therapy

Authors: Rachel N. Grisham, Carol Aghajanian, Els Van Nieuwenhuysen, Manuel Rodrigues, Kari L. Ring, Alessandro D. Santin, Nicoletta Colombo, Emily N. Prendergast, Premal H. Thaker, Katheen N. Moore, Erin A. Salinas, Isabelle Ray-Coquard, Hye Sook Chon, Peter G. Rose, Ana Oaknin, Andrew R. Clamp, Mitul D. Gandhi, Bradley J. Monk, Robert W. Holloway, Toon Van Gorp, Michel Fabbro, Christine Gennigens, Nicholas E. Wojtynek, Stephanie Lustgarten, Susana N. Banerjee

IGCS 2023 Annual Global Meeting, November 5-7, 2023, Seoul, South Korea

Initial Safety, Pharmacokinetics, and Recommended Phase 2 Dose from RAMP 203: A Phase 1/2 Study of Avutometinib + Sotorasib in KRAS G12C Mutant Non-Small Cell Lung Cancer

Authors: Mark M. Awad, Jerome Goldschmidt, Alexander I. Spira, Rajat Malhotra, Jeffrey T. Yorio, Vijeta Bhambhani, Yaofeng Cheng, Pablo S. Lee, Ramaswamy Govindan

AACR –NCI-EORTC 2023 October 14, 2023 Boston, MA

RAMP 205: A phase 1b/2a study of gemcitabine, nab-paclitaxel, avutometinib, and defactinib in untreated metastatic pancreatic ductal adenocarcinoma

Kian-Huat Lim, Manuel Hidalgo, Mark H. O'Hara, Kristen R. Spencer, Ignacio Garrido-Laguna, David G. DeNardo, Vijeta Bhambhani, Gloria Patrick, Yaofeng Cheng, Silvia Coma, Jonathan A. Pachter, Louis J. Denis

AACR SPECIAL CONFERENCE IN CANCER RESEARCH: PANCREATIC CANCER September 27, 2023

Rational Combinations of RAF/MEK Clamp Avutometinib; Breakthrough Therapy Designation and Beyond

Louis Denis, MD, Chief Medical Officer, Verastem Oncology

5th Annual RAS-Targeted Drug Development Summit September 27, 2023

RAF/MEK Clamp Avutometinib: Rational Combinations with FAK Inhibitor and Other Targeted Therapies

Jon Pachter, PhD, Chief Scientific Officer, Verastem Oncology

5th Annual RAS-Targeted Drug Development Summit September 28, 2023

The RAF/MEK clamp avutometinib as the backbone of therapy for pancreatic cancer: Novel combinations with standard of care chemotherapy, FAK inhibitors, KRAS G12D inhibitors and/or autophagy inhibitors

Silvia Coma, Xiuting Liu, Noah L. Pieper, Wen-Hsuan Chang, Kirsten L Bryant, Channing J Der, David G DeNardo, Jonathan A Pachter

AACR Special Conference in Cancer Research: Pancreatic Cancer; Boston September 27-30, 2023

The RAF/MEK clamp avutometinib induces an immunogenic tumor microenvironment and potentiates the efficacy of anti-PD-1

Silvia Coma1, Miriam Molina-Arcas2, Julian Downward2 & Jonathan A Pachter1 1Verastem Oncology, Needham, MA, USA; 2 The Francis Crick Institute, London, UK

AACR Annual Meeting; Orlando April 14-19, 2023

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP201: A phase 2 study of avutometinib ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

Authors: S. Banerjee, K. Ring, E. Van Niewenhuysen, M. Fabbro, C. Aghajanian, A. Oaknin, N. Colombo, A. Santin, A. Clamp, K. Moore, P. Rose, D. O'Malley, H. Sook Chon, E. Salinas, E. Prendergast, S. Lustgarten, M. Rodrigues, C. Gennigens, B. Monk, R. Grisham.

ASCO Annual Meeting June 2-6, 2023

RAMP 202: A phase 2 study of avutometinib ± defactinib in patients with advanced KRAS G12V mutant non-small cell lung cancer (NSCLC)

Authors: J. Reuss, S. Gandhi, D. Spigel, P. Janne, F. Gardner, L. Paz-Ares Rodriguez, S. Gadgeel, J. Patel, F. Passiglia, A. Spira, M. Edelman, G. Blumenschein, A. Shergill, T. Burns, V. Bhambhani, G. Patrick, J. Pachter, L. Denis, D. Camidge.

ASCO Annual Meeting June 2-6, 2023

The RAF/MEK clamp avutometinib induces an immunogenic tumor microenvironment and potentiates the efficacy of anti-PD-1

Silvia Coma1, Miriam Molina-Arcas2, Julian Downward2 & Jonathan A Pachter1 1Verastem Oncology, Needham, MA, USA; 2 The Francis Crick Institute, London, UK

AACR Annual Meeting; Orlando April 14-19, 2023

The RAF/MEK clamp avutometinib enhances antitumor efficacy of KRAS G12C and G12D inhibitors through vertical inhibition of RAS, RAF and MEK

Silvia Coma, Monica Musteanu, Cristina Caffarra, Alessia Mira, Enrico Patrucco, Julien Dilly, Andrew J Aguirre, Mariano Barbacid, Chiara Ambrogio & Jonathan A Pachter

AACR Special Conference: Targeting RAS March 5-8, 2023

The RAF/MEK Clamp Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers: Tumor/Biomarker-Specific Combination Strategies

Silvia Coma, Deborah K Morrison, Monica Musteanu, Chongkai Wang, Julien Dilly, Xiuting Liu, Udai Banerji, Ardaman Shergill, Andrew Aguirre, David G DeNardo, Mariano Barbacid, Marwan Fakih, Jonathan A Pachter

The Fourth RAS Initiative Symposium; October 17 - 19, 2022

Phase I trial of the RAF/MEK clamp Avutometinib in combination with everolimus

Authors: Minchom AR (1), Sanchez Perez V (1), Morton C (2), Manickavasagar T (1), Nintos G (3), Lai-Kwon JE (1), Guo C (1), Tunariu N (1), Parker T (4), Prout T (4), Parmar M (4), Turner AJ (4), Finneran L (4), Hall E (4), Pachter JA (5), Denis LJ (5), Spicer JF (3), Banerji U (1) 1. Drug Development Unit, The Institute of Cancer Research/The Royal Marsden Hospital NHS Foundation Trust, UK; 2. Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; 3. King's College London, London, UK ; 4. The Institute of Cancer Research, Sutton, UK; 5. Verastem Oncology, Needham, MA

ASCO Annual Meeting June 3-7, 2022

Mechanistic evaluation of Avutometinib (RAF/MEK clamp) and defactinib (FAK inhibitor) in low-grade serous ovarian cancer models with correlations to clinical response

Adam Stewart, Sara Diaz-Sanchez, Lisa Pickard, Ekta Paranjape, Victoria Sanchez Perez, Sanjib Chowdhury, Stephanie Lustgarten, Silvia Coma, Jonathan A Pachter, Mark Carey, Gabriel DiMattia, Hannah Badham, Toby Prout, Mona Parmar, Muneeb Mahmud, Christina Yap, Matthew Krebs, Susana Banerjee, Udai Banerji

AACR Annual Meeting - April 8-13, 2022

The RAF/MEK clamp Avutometinib enhances antitumor efficacy of KRAS G12C inhibitors through vertical inhibition of RAS, RAF and MEK

Silvia Coma, Sanjib Chowdhury, Julien Dilly, Monica Musteanu, Deborah K Morrison, Mariano Barbacid, Andrew J Aguirre & Jonathan A Pachter

AACR Annual Meeting - April 8-13, 2022

The RAF/MEK clamp Avutometinib for treatment of cutaneous melanoma harboring BRAF, NRAS, NF1 or RAF1 (CRAF) alterations

Antonella Bacchiocchi, Kamryn Carter, Silvia Coma, Sanjib Chowdhury, Deborah K Morrison, Mario Sznol, Ruth Halaban, Jonathan A Pachter

AACR Annual Meeting - April 8-13, 2022

Avutometinib: a Unique RAF/MEK Clamp for Treatment of KRAS Mutant NSCLC

Silvia Coma, Sanjib Chowdhury, Andrew Koustenis, Udai Banerji, Monica Musteanu, Mariano Barbacid, Deborah Morrison, Jonathan A. Pachter

Precision Lung Cancer Summit, January 26, 2022

Dual RAF/MEK inhibitor Avutometinib for treatment of solid tumors with diverse MAPK pathway alterations

Silvia Coma, Sanjib Chowdhury, Monica Musteanu, Mariano Barbacid, Jonathan A. Pachter

AACR-NCR-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021

Dual RAF/MEK inhibitor Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers

Silvia Coma, Sanjib Chowdhury, Andrew Koustenis, Udai Banerji, Susana Banerjee, Monica Musteanu, Mariano Barbacid, Marwan Fakih, Chongkai Wang, Jonathan Pachter

RAS Pathway-Driven Cancers, September 23, 2021

Dual RAF/MEK inhibitor Avutometinib for treatment of KRAS mutant NSCLC: Novel combinations targeting G12C or G12V variants

Silvia Coma, Sanjib Chowdhury, Monica Musteanu, Adam Stewart, Lisa Pickard, Matthew Krebs, Anna Mincho, Udai Banerji, Mariano Barbacid, Jonathan A. Pachter

IASLC 2021 World Conference on Lung Cancer, September 8-14, 2021

Phase I study of the combination of the dual RAF/MEK inhibitor Avutometinib and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer

S. Banerjee, R. Grochot, R. Shinde, J. Lima, M. Krebs, R. Rahman, M. Little, N. Tunariu, A. Curcean, H. Badham, M. Mahmud, A. Turner, M. Parmar, C. Yap, A. Minchom, J. Lopez, J. de Bono, U. Banerji.

2021 ESMO Congress

Dual RAF/MEK Inhibitor Avutometinib for Treatment of KRAS Mutant NSCLC: Novel Combinations Targeting G12V or G12C Variants

Jonathan Pachter, PhD, Chief Scientific Officer

NSCLC Drug Development Summit – July 14, 2021

Searching for Treatments for Non-G12C-KRAS Mutant Cancers

Christina Guo & Udai Banerji

British Journal of Cancer (2021) - April 15, 2021

FRAME: A Phase I Trial of the Combination of the Dual RAF/MEK Inhibitor Avutometinib and the FAK Inhibitor Defactinib; Evaluation of Efficacy in KRAS Mutated NSCLC

Matthew G. Krebs, Rajiv Shinde, Rozana Abdul Rahman, Rafael Grochot, Martin Little, Jenny King, Mark Van De Velde, Joseph Kitchin, Mona Parmar, Alison Turner, Muneeb Mahmud, Christina Yap, Nina Tunariu, Juanita Lopez, Johann S. de Bono, Udai Banerji, Anna Minchom

AACR Virtual Annual Meeting – April 10-15, 2021 & May 17-21, 2021

Dual RAF/MEK Inhibitor Avutometinib Enhances Anti-Tumor Efficacy of KRAS G12C Inhibitors Through a Vertical Pathway Inhibition Strategy

Silvia Coma, Sanjib Chowdhury, Jonathan A Pachter

AACR Virtual Annual Meeting – April 10-15, 2021 & May 17-21, 2021

Synergistic Antitumor Efficacy of the Dual RAF/MEK Inhibitor Avutometinib With FAK Inhibition for Treatment of RAS-Dependent Solid Tumors

Silvia Coma, Monica Musteanu, Justine S. Paradis, J. Silvio Gutkind, Mariano Barbacid, Jonathan A. Pachter

AACR Virtual Annual Meeting – April 10-15, 2021 & May 17-21, 2021

Synergistic Combinations With the Novel Dual RAF/MEK Inhibitor: Establishing Avutometinib as the Backbone of Therapy for RAS-Driven Cancers

Silvia Coma, Sanjib Chowdhury, Jonathan A. Pachter

RAS-Targeted Drug Discovery Summit – February 23-25, 2021

Synthetic Lethal Screens Reveal Co-Targeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma

Justine S. Paradis, Monica Acosta, Robert Saddawi-Konefka, Ayush Kishore, Frederico Gomes, Nadia Arang, Manoela Tiago, Silvia Coma, Simone Lubrano, Xingyu Wu, Kyle Ford, Chi-Ping Day, Glenn Merlino, Prashant Mali, Jonathan A. Pachter, Takami Sato, Andrew E. Aplin, J. Silvio Gutkind

Clinical Cancer Research. 2021 February 10; DOI: 10.1158/1078-0432.CCR-20-3363

Intermittent Schedules of the Oral RAF/MEK Inhibitor CH5126766/Avutometinib in Patients With RAS/RAF-Mutant Solid Tumours and Multiple Myeloma: a Single-Centre, Open-Label, Phase 1 Dose-Escalation and Basket Dose-Expansion Study

Christina Guo, Maxime Chénard-Poirier, Desamparados Roda, Maria de Miguel, Samuel J Harris, Irene Moreno Candilejo, Priya Sriskandarajah, Wen Xu, Mariana Scaranti, Anastasia Constantinidou, Jenny King, Mona Parmar, Alison J Turner, Suzanne Carreira, Ruth Riisnaes, Laura Finneran, Emma Hall, Yuji Ishikawa, Kiyohiko Nakai, Nina Tunariu, Bristi Basu, Martin Kaiser, Juanita Suzanne Lopez, Anna Minchom, Johann S de Bono, Udai Banerji

Lancet Oncology. 2020 October 28; 21 (11): 1478-1488. DOI: 10.1016/S1470-2045(20)30464-2

Synergistic Combinations With the Dual RAF/MEK Inhibitor Avutometinib to Overcome Resistance Mechanisms

Jonathan Pachter, PhD

RAS-Targeted Drug Development - September 16, 2020

Clinical Combinations: Dual RAF-MEK & FAK Inhibition for the Treatment of KRAS Mutant Cancers With a Focus on Low-Grade Serous Ovarian Cancer

Dr. Udai Banerji

RAS-Targeted Drug Development - September 16, 2020

Phase I Study of the Combination of a RAF/MEK Inhibitor CH5126766 and FAK Inhibitor Defactinib in an Intermittent Dosing Schedule With Expansions in KRAS Mutant Cancers

Rajiv Shinde, Angelika Terbuch, Martin Little, Reece Caldwell, Roopa Kurup, Ruth Riisnaes, Mateus Crespo, Ruth Ruddle, Bora Gurel, Adam Stewart, Jenny King, Mona Parmar, Alison Turner, Florence Raynaud, Muneeb Mahmud, Christina Yap, Jonathan A. Pachter, Gordon B. Mills, Anna Minchom, Juanita Lopez, Susana N. Banerjee, Johann S. de Bono, Matthew Krebs, Udai Banerji

AACR Session I April 24-29, 2020 & Session II June 22-24, 2020

Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors

Piro Lito, Anna Saborowski, Jingyin Yue, Martha Solomon, Eric Joseph, Sunyana Gadal, Michael Saborowski, Edward Kastenhuber, Christof Fellmann, Kazuhiro Ohara, Kenji Morikami, Takaaki Miura, Christine Lukacs, Nobuya Ishii, Scott Lowe, and Neal Rosen

Cancer Cell. 2014 May 12; 25(5): 697–710. doi:10.1016/j.ccr.2014.03.011

Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766 (avutometinib), That Suppresses Feedback Reactivation of RAF Activity

Nobuya Ishii, Naoki Harada, Eric W. Joseph, Kazuhiro Ohara, Takaaki Miura, Hiroshi Sakamoto, Yutaka Matsuda, Yasushi Tomii, Yukako Tachibana-Kondo, Hitoshi Iikura, Toshihiro Aoki, Nobuo Shimma, Mikio Arisawa, Yoshihiro Sowa, Poulikos I. Poulikakos, Neal Rosen, Yuko Aoki, and Toshiyuki Sakai

Cancer Res. 2013 July 1; 73(13): 4050–4060. doi:10.1158/0008-5472.CAN-12-3937

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual RAF/MEK Inhibitor in Patients With Solid Tumors

Maria Martinez-Garcia, Udai Banerji, Joan Albanell, Rastilav Bahleda, Saoirse Dolly, Françoise Kraeber-Bodéré, Federico Rojo, Emilie Routier, Ernesto Guarin, Zhi-Xin Xu, Ruediger Rueger, Jean J. L. Tessier, Eliezer Shochat, Steve Blotner, Valerie Meresse Naegelen and Jean-Charles Soria

Clin Cancer Res. 2012 September 1; (18) (17): 4806-4819. doi: 10.1158/1078-0432.CCR-12-0742

CRAF, but Not BRAF, Is Essential for Development of KRAS Oncogene-Driven Non-Small Cell Lung Carcinoma

Rafael B. Blasco, Sarah Francoz, David Santamaría, Marta Cañamero, Pierre Dubus, Jean Charron, Manuela Baccarini, and Mariano Barbacid

Cancer Cell. 2011 May 17; 19(5): 652–663. doi:10.1016/j.ccr.2011.04.002

Defactinib

Targeting FAK in Anticancer Combination Therapies

John C. Dawson, Alan Serrels, Dwayne G. Stupack, David D. Schlaepfer & Margaret C. Frame

Nature Reviews Cancer. 2021 March 17; doi.org/10.1038/s41568-021-00340-6

Phase I Study of Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer: Experiences of Pancreatic Ductal Adenocarcinoma (PDAC) Patients

Andrea Wang-Gillam, Robert McWilliams, A. Craig Lockhart, Benjamin R. Tan Jr., Rama Suresh, Kian-Huat Lim, Katrina S. Pedersen, Nikolaos Trikalinos, Olivia Aranha, Haeseong Park, Lee Ratner, Nicholas Boice, David G DeNardo.

AACR Session I April 24-29, 2020 & Session II June 22-24, 2020

Phase 2 Study of the Focal Adhesion Kinase Inhibitor Defactinib (VS-6063) in Previously Treated Advanced KRAS Mutant Non-Small Cell Lung Cancer

David E. Gerber, D. Ross Camidge, Daniel Morgensztern, Jeremey Cetnar, Ronan J. Kelly, Suresh S. Ramalingam, David R. Spigel, Woondong Jeong, Pier P. Scaglioni, Song Zhang, Marilyn Li, David T. Weaver, Louis Vaikus, Mitchell Keegan, Joanna C. Horobin, and Timothy F. Burns

Lung Cancer. 2020 Jan; 139: 60–67. doi: 10.1016/j.lungcan.2019.10.033

FAK Activity Sustains Intrinsic and Acquired Ovarian Cancer Resistance to Platinum Chemotherapy

Carlos J Diaz Osterman, Duygu Ozmadenci, Elizabeth G Kleinschmidt, Kristin N Taylor, Allison M Barrie, Shulin Jiang, Lisa M Bean, Florian J Sulzmaier, Christine Jean, Isabelle Tancioni, Kristen Anderson, Sean Uryu, Edward A Cordasco, Jian Li, Xiao Lei Chen, Guo Fu, Marjaana Ojalill, Pekka Rappu, Jyrki Heino, Adam M Mark, Guorong Xu, Kathleen M Fisch, Vihren N Kolev, David T Weaver, Jonathan A Pachter, Balázs Győrffy, Michael T McHale, Denise C Connolly, Alfredo Molinolo, Dwayne G Stupack, and David D Schlaepfer

eLife. 2019; 8: e47327. Published online 2019 Sep 3. doi: 10.7554/eLife.47327

Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity

Alan Serrels, Tom Lund, Bryan Serrels, Adam Byron, Rhoanne C. McPherson, Alexander von Kriegsheim, Laura Go´ mez-Cuadrado, Marta Canel, Morwenna Muir, Jennifer E. Ring, Eleni Maniati, Andrew H. Sims, Jonathan A. Pachter, Valerie G. Brunton, Nick Gilbert, Stephen M. Anderton, Robert J.B. Nibbs, and Margaret C. Frame

Cell. 2016 September 24; 163(1): 160-173. doi: 10.1016/j.cell.2015.09.001

Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy

Hong Jiang, Samarth Hegde, Brett L. Knolhoff, Yu Zhu1, John M. Herndon, Melissa A. Meyer, Timothy M. Nywening, William G. Hawkins, Irina M. Shapiro, David T. Weaver, Jonathan A. Pachter, Andrea Wang-Gillam, and David G. DeNardo

Nat Med. 2016 August; 22(8): 851–860. doi:10.1038/nm.4123

A Phase I Study of VS-6063, a Second-Generation Focal Adhesion Kinase Inhibitor, in Patients With Advanced Solid Tumors

Suzanne F Jones, Lillian L Siu, Johanna C Bendell, James M Cleary, Albiruni R A Razak, Jeffrey R Infante, Shuchi S Pandya, Philippe L Bedard, Kristen J Pierce, Brett Houk, W Gregory Roberts, S Martin Shreeve, Geoffrey I Shapiro

Invest New Drugs. 2015 Oct;33(5):1100-7. doi: 10.1007/s10637-015-0282-y